iShares US Pharmaceuticals ETF
101 hedge funds and large institutions have $317M invested in iShares US Pharmaceuticals ETF in 2017 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 16 increasing their positions, 47 reducing their positions, and 6 closing their positions.
120% more call options, than puts
Call options by funds: $860K | Put options by funds: $391K
117% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 6
6% more funds holding
Funds holding: 95 → 101 (+6)
0.25% more ownership
Funds ownership: 148.22% → 148.47% (+0.25%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
9% less capital invested
Capital invested by funds: $348M → $317M (-$30.7M)
66% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 47
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
+$9.64M |
| 2 |
Morgan Stanley
New York
|
+$9.25M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$6.13M |
| 4 |
Jane Street
New York
|
+$4.76M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$4.53M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
-$21.9M |
| 2 |
PAG
Pinnacle Advisory Group
Columbia,
Maryland
|
-$20.6M |
| 3 |
Goldman Sachs
New York
|
-$7.7M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$7.41M |
| 5 |
ST
Spinnaker Trust
Portland,
Maine
|
-$6.43M |
IHE Hedge Fund Activity: Q3 2017 in Review
101 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q3 2017, worth a combined $317M — down 8.8% from $348M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new IHE positions and 6 closed out — a net gain of 7 holders — while 16 added to existing stakes and 47 trimmed.
The largest buyer was Two Sigma Securities, adding an estimated $9.64M. The largest seller was Clal Insurance, cutting an estimated $21.9M.
- 101 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q3 2017, up from 95 in Q2 2017.
- Funds reported $317M of iShares US Pharmaceuticals ETF stock for Q3 2017, down 8.8% quarter-over-quarter.
- 13 funds opened new iShares US Pharmaceuticals ETF positions in Q3 2017 and 6 closed out, a net change of +7 holders.
- The largest iShares US Pharmaceuticals ETF buyer in Q3 2017 was Two Sigma Securities, an estimated $9.64M added.
- The largest iShares US Pharmaceuticals ETF seller in Q3 2017 was Clal Insurance, an estimated $21.9M sold.
Based on aggregated 13F filings for Q3 2017.